PSEN1 S169del (ΔS169)

Other Names: ΔS169, Ser169del, ΔS170


Pathogenicity: Alzheimer's Disease : Pathogenic
ACMG/AMP Pathogenicity Criteria: PS3, PM1, PM2, PP1, PP3
Clinical Phenotype: Alzheimer's Disease
Reference Assembly: GRCh37/hg19
Position: Chr14:73653587_73653589 ATC>---
Coding/Non-Coding: Coding
DNA Change: Deletion
Expected RNA Consequence: Deletion
Expected Protein Consequence: Deletion
Codon Change: TCA.TCT to TCT
Reference Isoform: PSEN1 Isoform 1 (467 aa)
Genomic Region: Exon 6


This trinucleotide deletion mutation has been reported in a family from southern China (Guo et al., 2010). The pedigree contains four affected individuals in three generations. The clinical presentation in this family is fairly typical for AD. In contrast to the other reported mutations at the 169 codon, S169del does not appear to be associated with myoclonus, seizures, or pronounced personality changes. The proband developed progressive memory impairment at age 42, especially difficulties with short-term memory. Her mother developed similar symptoms at age 50 and died at age 60. A maternal aunt and uncle were also affected, with symptom onset at ages 42 and 45, the aunt dying at age 50 and the uncle alive at the time of the report (age 50). The mutation was detected in the two affected individuals tested as well as in two young family members (age 22 and 24) who were currently healthy, but suspected to be presymptomatic. The mutation was absent in three other unaffected family members and in 100 unrelated controls. It was also absent from the gnomAD variant database (gnomAD v2.1.1, June 2021).


Unknown; MRI of the proband showed generalized cerebral atrophy with enlargement of the ventricles and widening of the sulci (Guo et al., 2010).

Biological Effect

This is a trinucleotide deletion which includes the last nucleotide of the serine 169 codon and the first two nucleotides of the serine 170 codon. The consequence is loss of one serine which can be mapped to either S169 or S170, and hence, the mutation has been referred to as S169del or S170del. In an in vitro assay using purified proteins to test the ability of this mutant to cleave the APP-C99 substrate, Aβ42 production was robustly decreased and Aβ40 production was undetectable (Sun et al., 2017). In contrast, the mutation was reported to leave Notch 1 cleavage and Notch signaling intact, both in vitro and in vivo (Zhang et al., 2018). However, cryo-electron microscopy studies indicate that, in wild-type PSEN1, serine 169 helps anchor the interface between PSEN1and both APP and Notch fragments; its hydroxyl group forming H-bonds with carbonyl oxygen atoms in each of the two substrates (Zhou et al., 2019; Jan 2019 newsYang et al., 2019). In silico algorithms to predict the effects of this variant on protein function yielded conflicting results (Xiao et al., 2021).


Alzheimer's Disease : Pathogenic

This variant fulfilled the following criteria based on the ACMG/AMP guidelines. See a full list of the criteria in the Methods page.


Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product. S169del: Aβ42/Aβ40 ratio increased, but production of both peptides decreased.


Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation. S169del: Variant is in a mutational hot spot and cryo-EM data suggest residue is of functional importance.


Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. *Alzforum uses the gnomAD variant database.


Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease: *Alzforum requires at least one affected carrier and one unaffected non-carrier from the same family to fulfill this criterion. S169del: At least one family with 2 affected carriers and >=1 unaffected noncarriers.


Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). *In most cases, Alzforum applies this criterion when the variant’s PHRED-scaled CADD score is greater than or equal to 20.

Pathogenic (PS, PM, PP) Benign (BA, BS, BP)
Criteria Weighting Strong (-S) Moderate (-M) Supporting (-P) Supporting (-P) Strong (-S) Strongest (BA)

Last Updated: 22 Feb 2022


No Available Comments

Make a Comment

To make a comment you must login or register.


News Citations

  1. CryoEM γ-Secretase Structures Nail APP, Notch Binding

Paper Citations

  1. . A novel presenilin 1 mutation (Ser169del) in a Chinese family with early-onset Alzheimer's disease. Neurosci Lett. 2010 Jan 1;468(1):34-7. Epub 2009 Oct 22 PubMed.
  2. . Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase. Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E476-E485. Epub 2016 Dec 5 PubMed.
  3. . A presenilin-1 mutation causes Alzheimer disease without affecting Notch signaling. Mol Psychiatry. 2018 Jun 18; PubMed.
  4. . Recognition of the amyloid precursor protein by human γ-secretase. Science. 2019 Feb 15;363(6428) Epub 2019 Jan 10 PubMed.
  5. . Structural basis of Notch recognition by human γ-secretase. Nature. 2019 Jan;565(7738):192-197. Epub 2018 Dec 31 PubMed.
  6. . APP, PSEN1, and PSEN2 Variants in Alzheimer's Disease: Systematic Re-evaluation According to ACMG Guidelines. Front Aging Neurosci. 2021;13:695808. Epub 2021 Jun 18 PubMed.

External Citations

  1. gnomAD v2.1.1

Further Reading

No Available Further Reading

Protein Diagram

Primary Papers

  1. . A novel presenilin 1 mutation (Ser169del) in a Chinese family with early-onset Alzheimer's disease. Neurosci Lett. 2010 Jan 1;468(1):34-7. Epub 2009 Oct 22 PubMed.

Other mutations at this position


Disclaimer: Alzforum does not provide medical advice. The Content is for informational, educational, research and reference purposes only and is not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on Alzforum.